Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Mission Wealth Management LP

Mission Wealth Management LP raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 471 shares of the biopharmaceutical company’s stock after purchasing an additional 19 shares during the quarter. Mission Wealth Management LP’s holdings in Regeneron Pharmaceuticals were worth $414,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. FMR LLC increased its stake in shares of Regeneron Pharmaceuticals by 7.3% in the third quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock worth $8,098,661,000 after acquiring an additional 669,517 shares during the period. Northern Trust Corp increased its stake in shares of Regeneron Pharmaceuticals by 3.3% in the third quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock worth $878,271,000 after acquiring an additional 34,326 shares during the period. Morgan Stanley increased its stake in shares of Regeneron Pharmaceuticals by 2.7% in the third quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company’s stock worth $799,061,000 after acquiring an additional 25,792 shares during the period. American Century Companies Inc. boosted its holdings in Regeneron Pharmaceuticals by 3.4% during the third quarter. American Century Companies Inc. now owns 916,718 shares of the biopharmaceutical company’s stock worth $754,422,000 after buying an additional 30,050 shares in the last quarter. Finally, International Assets Investment Management LLC boosted its holdings in Regeneron Pharmaceuticals by 76,169.5% during the fourth quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock worth $519,148,000 after buying an additional 590,314 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

REGN has been the topic of a number of recent analyst reports. BMO Capital Markets increased their price target on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a report on Monday, February 5th. Truist Financial reaffirmed a “buy” rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Bank of America increased their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a report on Friday, April 12th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $925.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $977.77.

Regeneron Pharmaceuticals Trading Up 2.1 %

NASDAQ REGN opened at $957.00 on Friday. The firm has a 50 day simple moving average of $944.24 and a 200-day simple moving average of $895.54. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 6.40. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33. The firm has a market cap of $105.04 billion, a price-to-earnings ratio of 28.27, a PEG ratio of 2.69 and a beta of 0.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping the consensus estimate of $10.73 by $1.13. The business had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The company’s quarterly revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $10.96 earnings per share. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.86 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the transaction, the director now owns 18,282 shares in the company, valued at approximately $17,953,838.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $982.05, for a total transaction of $98,205.00. Following the completion of the sale, the director now directly owns 18,282 shares in the company, valued at $17,953,838.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the sale, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. Insiders sold 10,095 shares of company stock valued at $9,664,476 in the last three months. 8.83% of the stock is owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.